UTHR is United Therapeutics Corporation (Healthcare) — a non-dividend-paying stock. Trading at $587.50. Market cap: $25.20B. Capital Quality Rank: 99/100 — Market alpha.
Stock snapshot
| Price | $587.50 |
| Market cap | $25.20B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 99 / 100 · Market alpha |
| ROIC (TTM) | 21.3% |
| Revenue CAGR (3y) | 18.0% |
| Shareholder buyback yield | 1.25% |
| Altman Z-score zone | Safe |
Valuation, price chart & technicals
Valuation Multiples— the whole story at a glance
vs 1073 Healthcare peers (median)PEG colour: ≤ 1.0 cheap · 1–2 fair · > 2 rich. Lower = the stock's price is rising slower than its growth.
Price Chart
+37.84%Technicals
About UTHR
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Related non-dividend companies
Other non-dividend stocks investors research alongside UTHR. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is UTHR's current stock price?
UTHR (United Therapeutics Corporation) is currently trading at $587.50.
Does UTHR pay a dividend?
UTHR (United Therapeutics Corporation) does not currently pay a regular dividend.
What is UTHR's Capital Quality Rank?
UTHR has a Capital Quality Rank of 99/100 — Market alpha. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track UTHR in DiviDrip
Add UTHR to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search UTHR and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-10-25. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.